Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo

Clinical Cancer Research

Volumn 13, Issue 3, 2007, Pages 1036-1044

  Ponthan, Frida ^a,b   Wickström, Malin ^c   Gleissman, Helena ^a   Fuskevåg, Ole M ^d   Segerström, Lova ^a   Sveinbjörnsson, Baldur ^a   Redfern, Christopher P F ^b   Eksborg, Staffan ^a   Kogner, Per ^a,e   Johnsen, John I ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; ETOPOSIDE; IRINOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; CYTOTOXICITY; DIET; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; KI-67 ANTIGEN; MALE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; PYRAZOLES; RATS; RATS, NUDE; SULFONAMIDES;

EID: 33847407482     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1908     Document Type: Article

References (50)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
2. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82.
3. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529-36.
4. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
5. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
6. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anti-cancer agents? Lancet Oncol 2003;4:605-15.
7. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
8. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000;60:4705-8.
9. Thun MJ, Henley SJ, Patrono C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
10. Tiano HF, Loftin CD, Akunda J, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62:3395-401.
11. Ulrich CM, Bigler J, Potter JD. Non-steroidal antiinflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6:130-40.
12. Dang CT, Dannenberg AJ, Subbaramaiah K, et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res 2004;10:4062-7.
13. Reardon DA, Quinn JA, Vredenburgh J, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 2005;103:329-38.
14. Reckamp KL, Krysan K, Morrow JD, et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 2006;12:3381-8.
15. Pruthi RS, Derksen JE, Moore D, et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 2006;12:2172-7.
16. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006;24:2723-8.
17. Johnsen JI, Lindskog M, Ponthan F, et al. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 2004;64:7210-5.
18. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 2001;21:3425-32.
19. Fife RS, Stott B, Carr RE. Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro. Cancer Biol Ther 2004;3:228-32.
20. Howe LR, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002;62:5405-7.
21. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-403.
22. Kundu N, Fulton AM. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002;62:2343-6.
23. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004;23:63-75.
24. Liao Z, Komaki R, Milas L, et al. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status in-operable/unresectable non-small cell lung cancer. Clin Cancer Res 2005;11:3342-8.
25. Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A. The selective Cox-2 inhibitor celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer 2006;6:9.
26. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005;27:573-81.
27. Dunne A. JANA: a new iterative polyexponential curve stripping program. Comput Methods Programs Biomed 1985;20:269-75.
28. Ponthan F, Johnsen JI, Klevenvall L, Castro J, Kogner P. The synthetic retinoid RO 13-6307 induces neuroblastoma differentiation in vitro and inhibits neuroblastoma tumour growth in vivo. Int J Cancer 2003;104:418-24.
29. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992;50:177-85.
30. Rickardson L, Fryknas M, Haglund C, et al. Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemother Pharmacol 2006;58:749-58.
31. Lovat PE, Ranalli M, Bernassola F, et al. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. Int J Cancer 2000;88:977-85.
32. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
33. Stempak D, Gammon J, Klein J, Koren G, Baruchel S. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther 2002;72:490-7.
34. Johnsen JI, Lindskog M, Ponthan F, et al. NSAIDs in neuroblastoma therapy. Cancer Lett 2005;228:195-201
35. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-66.
36. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 2005;115:484-92.
37. Trifan OC, Durham WF, Salazar VS, et al. Cyclooxygenase-2 inhibition with celecoxib enhances anti-tumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002;62:5778-84.
38. Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer 2004;11:129-33.
39. Sanborn R, Blanke CD. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust? Semin Oncol 2005;32:69-75.
40. Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 2005;131:31-40.
41. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective non-steroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006;113:1950-7.
42. Levesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 2006;174:1563-9.
43. Nelson NJ. Celecoxib shown effective in preventing colon polyps. J Natl Cancer Inst 2006;98:665-7.
44. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
45. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62:625-31.
46. Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11:1999-2007.
47. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002;33:708-14.
48. Sawaoka H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998;274:G1061-7.
49. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-5.
50. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-94.